PND-1186: A Potent FAK Inhibitor for Cancer Research
Discover the power of PND-1186, a leading FAK inhibitor designed to target tumor cell apoptosis and metastasis, offering new avenues for cancer treatment and research.
Get a Quote & SampleProduct Core Value
FAK Inhibitor
As a premier supplier in China, we offer PND-1186, a highly potent and selective Focal Adhesion Kinase (FAK) inhibitor. With an IC50 of 1.5 nM, this compound is instrumental in cancer research, enabling targeted apoptosis and significantly impacting tumor growth and metastasis. Our commitment as a manufacturer in China ensures high quality and reliability for your critical research needs.
- Leveraging potent FAK inhibitor properties, PND-1186 selectively promotes tumor cell apoptosis, a key mechanism in cancer therapy.
- As a selective FAK inhibitor, PND-1186 demonstrates efficacy in inhibiting tumor growth and metastasis in preclinical cancer models, offering valuable insights for drug development.
- Experience the benefits of PND-1186's oral bioavailability, a crucial factor for effective drug delivery and patient compliance in potential future cancer treatments.
- Explore the potential of PND-1186 in targeted cancer therapy, understanding its role in disrupting cancer cell signaling pathways and hindering disease progression.
Advantages Offered by PND-1186
Enhanced Specificity
PND-1186 acts as a selective FAK inhibitor, minimizing off-target effects and allowing researchers to focus on specific cellular processes crucial for understanding cancer biology.
Potent Anti-tumor Activity
With a low IC50 value, PND-1186 exhibits potent activity in promoting tumor cell apoptosis and inhibiting both tumor growth and metastasis, making it a valuable tool in preclinical cancer research.
Orally Bioavailable
The oral bioavailability of PND-1186 simplifies administration in preclinical studies and holds promise for future therapeutic applications, aligning with the goal of finding effective tumor growth inhibition drugs.
Key Applications
Cancer Therapy Research
PND-1186 is pivotal in researching novel cancer therapies, particularly those targeting FAK signaling pathways to induce apoptosis and halt disease progression.
Metastasis Inhibition Studies
Investigate the mechanisms of cancer metastasis with PND-1186, as it has demonstrated significant ability to decrease tumor metastasis in preclinical models.
Apoptosis Induction Research
Utilize PND-1186 to explore and understand the pathways that trigger programmed cell death in cancer cells, a fundamental aspect of cancer treatment development.
Drug Development Pipeline
Incorporate PND-1186 into your drug development pipeline as a key compound for targeting FAK-related cancers, aiming for effective tumor growth inhibition.